OncoMatch/Clinical Trials/NCT06793449
BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma
Is NCT06793449 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including anti-BCMA CAR-T and ASCT for multiple myeloma.
Treatment: anti-BCMA CAR-T · ASCT — This is a prospective, non-inferiority study comparing VRD±D followed by BCMA CAR-T cell therapy versus VRD±D followed by autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma patients.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Biomarker criteria
Required: BCMA (TNFRSF17) expression (confirmed expression of the BCMA target antigen on MM cells)
Confirmed expression of the BCMA target antigen on MM cells by flow cytometry or bone marrow immunohistochemistry
Demographics
Prior therapy
Cannot have received: bcma-targeted therapy
Cannot have received: car-t cell therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06793449 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior bcma-targeted therapy, car-t cell therapy disqualifies patients from enrollment.
Does this trial require TNFRSF17?
Yes, TNFRSF17 expression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages